These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 12108090)

  • 1. [Broad-spectrum beta-lactamases. Clinical significance and detection methods].
    Sidorenko SV
    Antibiot Khimioter; 2001; 46(12):27-34. PubMed ID: 12108090
    [No Abstract]   [Full Text] [Related]  

  • 2. [Study on prevalence and molecular mechanisms of antibacterial resistance in Gram-negative pathogens of nosocomial infections in hospitals of Moscow and Perm'].
    Mudrak DE; Ikriannikova LN; Sidorenko SV; Il'ina EN
    Antibiot Khimioter; 2007; 52(7-8):10-6. PubMed ID: 18986019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A choice of antibacterial chemotherapy for nosocomial infections caused by pathogens producing broad-spectrum beta-lactamases].
    Beloborodov VB
    Antibiot Khimioter; 2001; 46(12):3-7. PubMed ID: 12108091
    [No Abstract]   [Full Text] [Related]  

  • 4. Acquired metallo-beta-lactamases: an increasing clinical threat.
    Rossolini GM
    Clin Infect Dis; 2005 Dec; 41(11):1557-8. PubMed ID: 16267726
    [No Abstract]   [Full Text] [Related]  

  • 5. New β-lactam antibiotics and β-lactamase inhibitors.
    Bush K; Macielag MJ
    Expert Opin Ther Pat; 2010 Oct; 20(10):1277-93. PubMed ID: 20839927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Version 2000: the new beta-lactamases of Gram-negative bacteria at the dawn of the new millennium.
    Thomson KS; Smith Moland E
    Microbes Infect; 2000 Aug; 2(10):1225-35. PubMed ID: 11008112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta-lactamase detection in nosocomial bacterial pathogens in Lagos, Nigeria.
    Kesah CN; Odugbemi TO
    Niger Postgrad Med J; 2002 Dec; 9(4):210-3. PubMed ID: 12690681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms.
    Jones RN; Sader HS; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 May; 52(1):71-4. PubMed ID: 15878447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissemination of IncF plasmids carrying beta-lactamase genes in Gram-negative bacteria from Nigerian hospitals.
    Ogbolu DO; Daini OA; Ogunledun A; Terry Alli OA; Webber MA
    J Infect Dev Ctries; 2013 May; 7(5):382-90. PubMed ID: 23669427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the development of β-lactamase inhibitors.
    Jalde SS; Choi HK
    J Microbiol; 2020 Aug; 58(8):633-647. PubMed ID: 32720096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbapenemases: a brief review for pediatric infectious disease specialists.
    Overturf GD
    Pediatr Infect Dis J; 2010 Jan; 29(1):68-70. PubMed ID: 20035208
    [No Abstract]   [Full Text] [Related]  

  • 12. Extended-spectrum beta-lactamases: the role of inhibitors in therapy.
    Amyes SG; Miles RS
    J Antimicrob Chemother; 1998 Oct; 42(4):415-7. PubMed ID: 9818738
    [No Abstract]   [Full Text] [Related]  

  • 13. [Available carbapenems: Properties and differences].
    Martínez MJ; García MI; Sánchez EG; Sánchez JE
    Enferm Infecc Microbiol Clin; 2010 Sep; 28 Suppl 2():53-64. PubMed ID: 21130931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Extended spectrum beta lactamase forming pathogens (ESBL)].
    Gastmeier P
    Med Klin Intensivmed Notfmed; 2012 Nov; 107(8):592-3. PubMed ID: 23138656
    [No Abstract]   [Full Text] [Related]  

  • 15. Detection of expanded-spectrum β-lactamases in Gram-negative bacteria in the 21st century.
    Al-Bayssari C; Dabboussi F; Hamze M; Rolain JM
    Expert Rev Anti Infect Ther; 2015; 13(9):1139-58. PubMed ID: 26162631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the Blue-Carba test for rapid detection of carbapenemases in gram-negative bacilli.
    Pasteran F; Veliz O; Ceriana P; Lucero C; Rapoport M; Albornoz E; Gomez S; Corso A;
    J Clin Microbiol; 2015 Jun; 53(6):1996-8. PubMed ID: 25809971
    [No Abstract]   [Full Text] [Related]  

  • 17. Influence of disk preparation on detection of metallo-beta-lactamase-producing isolates by the combined disk assay.
    Andrade SS; Picão RC; Campana EH; Nicoletti AG; Pignatari AC; Gales AC
    J Clin Microbiol; 2007 Jun; 45(6):2058-60. PubMed ID: 17409202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissemination of the metallo-beta-lactamase gene blaIMP-4 among gram-negative pathogens in a clinical setting in Australia.
    Peleg AY; Franklin C; Bell JM; Spelman DW
    Clin Infect Dis; 2005 Dec; 41(11):1549-56. PubMed ID: 16267725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emerging threat of acquired carbapenemases in Gram-negative bacteria.
    Cornaglia G; Rossolini GM
    Clin Microbiol Infect; 2010 Feb; 16(2):99-101. PubMed ID: 20085603
    [No Abstract]   [Full Text] [Related]  

  • 20. Determination of extended spectrum beta-lactamases, metallo-beta-lactamases and AmpC-beta-lactamases among carbapenem resistant Pseudomonas aeruginosa isolated from burn patients.
    Neyestanaki DK; Mirsalehian A; Rezagholizadeh F; Jabalameli F; Taherikalani M; Emaneini M
    Burns; 2014 Dec; 40(8):1556-61. PubMed ID: 24767143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.